International Scientific Information, Inc.’s Post

Dear Colleagues, A recent article in the American Journal of Case Reports by authors from Prince of Songkla University, Thailand, describes a case of advanced-stage hepatocellular carcinoma with rare orbital metastasis. Highlighting the importance of recognizing orbital metastasis as an initial HCC sign, the patient was treated successfully using dual immunotherapy (durvalumab - tremelimumab) combined with radiotherapy, showing significant clinical improvement and decreased alpha-fetoprotein levels. This underscores dual immunotherapy's potential in treating advanced HCC with orbital metastasis and need for early diagnostic investigations in at-risk patients. The complete report is available on the American Journal of Case Reports webpage. | https://lnkd.in/d6Dv-ZhT

By combining radiotherapy (RT), the safety and efficacy of CAR-T can be improved. RT can serve as bridging therapy, reducing the tumor burden before CAR-T infusion, thus enabling safe and successful CAR-T infusion, and as salvage therapy in cases of CAR-T therapy failure. 

Transarterial chemoembolization plus sorafenib as postop adjuvant therapy in patients with hepatocellular carcinoma with portal vein tumor thrombus resulted in longer recurrence-free survival & overall survival than sorafenib alone. https://ja.ma/3VPibMB

Check out the latest CIRSE Library topic package on intermediate-stage HCC! ➡️ https://t.ly/FPjrC Hepatocellular carcinoma (HCC) can be described as "intermediate" based on its pathological features and clinical features. Intermediate-stage HCC encompasses the widest class of patients with extensively heterogeneous tumours that may differ in number, size, and location. Following BCLC classification, TACE is the therapeutic modality of choice. However, other treatment modalities are currently employed, such as thermal ablation, radioembolization, combined treatments with or without balloon-inflatable microcatheters, and systemic therapies. This topic package, curated by Renato Argiró, showcases lectures, guidelines, and academy courses, as well as further reading on the treatment of intermediate-stage HCC. #interventionalradiology #CIRSElibrary #InterventionalOncology

Register for the GEST Journal Club. Drs Shamar Young, Beau Bosko Toskich, Mohammad Khreiss, Riad Salem, and Sudhir Manda will be reviewing the publication: EPOCH (Evaluating #TheraSphere in Patients with metastatic colorectal carcinoma Of the liver who have progressed on first-line Chemotherapy) is the first study to investigate the role of transarterial #radioembolization with Yttrium-90 (TARE) when added to standard-of-care second-line chemotherapy for colorectal liver metastases. March 19. Register here: https://lnkd.in/gysKAJHF #interventionalradiology #IR #embolotherapy #embolization #IRads #MedEd #interventionaloncology #IRadres  Boston Scientific

🏥 Sirtex Medical Limited unveils SIR-Spheres FLEXdose SELECT Delivery for Y-90 therapy SIR-Spheres FLEXdose SELECT introduces a new method for delivering precise Y-90 selective internal radiation therapy to treat liver tumours originating from primary colorectal cancer. SIR-Spheres are a medical device used in selective internal radiation therapy. It is specifically indicated for use in conjunction with intra-hepatic artery chemotherapy (IHAC) using FUDR (Floxuridine). Read more online: https://lnkd.in/e78WcWQX 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

Take the JAMA Clinical Challenge A 51-year-old male reported a 4-week history of redness and swelling of the right temporal bulbar conjunctiva was referred for evaluation of a choroidal lesion in the right eye. He had a history of BRAF V600E mutation—positive, superficial spreading type cutaneous melanoma (CM) on the chest with metastasis to a sentinel lymph node 3 years ago. What would you do next? Comment your answer below. A. Plaque radiotherapy B. Enucleation C. Fine-needle aspiration D. Observation Tomorrow at 12 pm ET we’ll post the answer.

The primary objective of this study is to assess the effectiveness of ONC201 in treating glioma patients following radiation therapy. The study aims to evaluate the safety and tolerability of ONC201 compared to a placebo (a capsule that looks like ONC201 but does not contain any active drug) and investigate if ONC201 can improve the quality of life and brain functioning in people with glioma. You may be eligible for this study if: You are 18 years or older. You have a newly diagnosed H3 K27M-mutant diffuse midline glioma and it has not recurred following standard treatment. You have completed or plan to complete standard frontline radiotherapy within 12 weeks from initial diagnosis. Enroll by visiting Ivy Brain Tumor Center's website!

Waiting for #ECIO2024 Ablation Prediction and Confirmation for liver metastases from colorectal carcinoma (CRC) using XperGuide Software (Philips). 81 years old patient affected by two CRC metastases detected during MR follow-up. After catheterization of the hepatic artery, Dual-Phase CBCT was performed to detect the lesions and segmented using a dedicated software (XperGuide, Philips). After US-guided MW antenna (Emprint, Medtronic) placement in each lesion, a new CBCT was performed and superimposed to the first one to assess correct placement and evaluate the best ablation protocol to cover lesions and margins thanks to Ablation Prediction software.  After ablation, a new Dual-Phase CBCT was performed, and volume of the ablations segmented and superimposed with the segmented lesions. Residual tumor was detected and treated with an additional ablation. Final Dual-Phase CBCT and segmentation showed complete coverage of the segmented lesion within the ablation volume. European Conference on Interventional Oncology pushing boundaries of Interventional Oncology. #InterventionalOncology #IO #InterventionalRadiology #IR #ablation #navigation #verification #confirmation #liver #mets #LodIR Antonio Pio Francioso Maurizio Papa ASST Lodi - Azienda Socio Sanitaria Territoriale di Lodi

Pancreatic Adenocarcinoma Crash Course # 5 Tumor localized to the pancreas --> best survival --> complete resection. Tumor invading surrounding structures like blood vessels --> survival = 1 yr. Distant metastases --> survival = 6 months. Treatment: Tumor localized to the pancreas --> complete resection --> curative. Tumor invading surrounding blood vessels --> chemotherapy/radiation --> shrink the tumor --> resection. Please like, follow, share, repost, and comment if you like my content. I try my best to respond to every comment personally. If you want to see all of my future posts, hit the bell icon next to my profile. If you want to see all of my videos, please subscribe to my YouTube channel here. https://lnkd.in/gGg7KuBt